Acadia Investor Says Officers Overhyped Drug's Prospects
An investor in biopharmaceutical company Acadia Pharmaceuticals Inc. has filed a derivative shareholder suit against the company's brass in San Diego federal court alleging the executives misrepresented its chances of receiving...To view the full article, register now.
Already a subscriber? Click here to view full article